Helix BioPharma Partners with ProMab on CAR-T Therapies
The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.
Helix BioPharma, an immuno-oncology company, has signed a collaboration agreement with ProMab Biotechnologies to develop novel antibody and chimeric antigen receptor T-cell (CAR-T) therapy for particular hematological malignancies, such as multiple myeloma, the company announced in a March 21, 2018 press release.
Helix had previously announced the signing of a binding letter of intent with ProMab to develop CAR-T for various hematological malignancies and solid tumors. The company has now signed its first scientific collaboration to co-develop a cell-based therapy for multiple myeloma (MM).
The MM co-development program will aim to complete all necessary work and intends to file for a first-in-human study by early 2019. Under the agreement, Helix will retain commercial rights for this CAR-T product in Canada and Europe and is currently in the process of reviewing the expansion criteria required for its European operations in Poland to facilitate commercialization.
Source: Helix BioPharma
